抄録_46回中国地方会37-6_責.indd
|
|
|
- くにひと わにべ
- 9 years ago
- Views:
Transcription
1 Update 46-1 Gd-EOB-DTPA MRI EOB-MRI HCC dysplastic nodule DN HCC 23 DN B hypoechoic 67 46%hyperechoic 79 54% bright loop 14% A dynamic MDCT iso density EOB-MRI 24 B CT low density 122 B A/B hypoechoic 75%/40%, hyperechoic 25%/60% P=0.001 MRI T1 A 6 25% B 69 57% P=0.004 EOB-MRI B 46-2 CTHA/CTAP 79 C CT MRI S4 4cm CTHA CTAP EOB-MRI TIWI T2WI Sonazoid US hypo echoic 30 2 iso echoic post vascular phase defect S4 US 46-3 planning sonography RVSCEUS RVS CEUS good 9 fair 28 poor 12 invisible 3 good RVS fair poor invisible RVS CEUS % 7.7% RVS CEUS 46-4 Sonazoid Sonazoid Sonazoid 15 Mechanical Index:0.2 focus TIC Sonazoid 0.010ml/kg TIC , PT BMI Spleen Index Sonazoid 46-5 Sonazoid CT 80mm
2 CT MRI Sonazoid 46-6 Sonazoid 70 B CT EOB-MRI Sonazoid Vascular phase Post-vascular phase Re-injection 6 5HIAA 46-7 Sonazoid DIC B Sonazoid CEUS defect 1 defect B Sonazoid CEUS mm FNH 3 10mm FNH CT S4 S5 S4 8-10mm B 3 central satellite scar spoke wheel appearance Sonazoid early arterial phase spoke wheel appearance late vascular phase Kupffer phase FNH HCC size FNH H21 5 H22 6 CT Sonazoid ml 5%EOI Hct 5.9% C AFP PIVKA 4 SOL 3 HCC S2 S2 10 US 12 CT US S2 S2 halo Sonazoid S2 S2 S2 HCC spleen index cm CT
3 2cm 21G PBC 22 2 S8 16mm Sonazoid early vascular phase late vascular phase Kupffer phase color doppler vascular phase penetrating vessel non-hodgkin lymphoma low grade B-cell lymphomapbc color doppler CT MRI hypovascular metastasis color Doppler 15 metastasis retrospective review B-mode color Doppler hypervascular CT MRI CT MRCP T-Bil3.7mg/dl ERCP EUS US hypovascular tumor EUSFNA US US US CT MRI ERCP 50% IgG4 IgG4 / EUS-FNA 1 46 LDH IgG US CT MRI DWI EUS capsule like rim ERCP EUS-FNA PET-CT FDG Burkitt lymphoma
4 DIC-CT 15mm EUS 2cm. 2cm ss 76 US 8mm 14mm EUS C 132 FibroScan Child Pugh Child Pugh P3P4 7s C C C 3 C FibroScan KPa HCV AdaBoost 12 8 Cross-Validation 56% 85% Virtual touch tissue quantification Virtual touch tissue quantification VTTQ (FIB4-index APRI VTTQ / 57/48 HBV/HCV 26/79 F cut off AUROC VTTQ; F1/2: F2/3; F3/4; FIB4;F1/2:17.13( F2/3: F3/4:46.7( APRI;F1/2: F2/3:9.93( F3/4:
5 0.552 VTTQ VTTQ C C C 66 TOSHIBA APLIO XG F -3, A1-3 HARI, HAPI, SARI, SAPI, PVVmean Alb AST ALT -GTP, PLT SAPI SARI SAPI AST ALT AST ALT Update EUS ESD EMR, ESD EUS EMR,ESD % % % % EMR, ESD m sm % 4 31% 3 75% 3 23% EUS EUS m 1mm sm 1mm m/sm EUS-m m/sm sm AD EUS-m 80.8% 194/240 EUS-sm 57.1% 28/49 8 EUS-m/sm 80.0% m 20.0% sm EUS mp se n=33 mp 4 5 ss 5 ss 5 se ss 5
6 CT free air 5 US 30mm SMA cm SMA SMA sandwich sign Castleman CT PET/CT 200cm 50cm myofibroblast CT MRI CT S 2cm 1 2cm X US S US 20 / 3 US US S - US S
7 46-34 US EUS Sonazoid US EUS US EUS FNA IPMN 14 mucus debris 1 NET 2 SPN 1 2 Sonazoid IPMN mm CT,MRI EUS-FNA 9 3 4cm CT Sonazoid EUS-FNA IPMN 70 45mm 8.5mm 3 9 MRI Sonazoid 15mm ERCP ENPD IPMC D paillary fibroelastoma 72 Debakey ,,aVF ST 2D flap CT STEMI 100% flow flow 3D 10mm 3D paillary fibroelastoma mm P mm
8 3D adenocarcinoma PET-CT FDG isoechoic 16 10mm 4 12 PET-CT RT area trace 70 80% PSV peak systolic velocity 2.5m/s 1.7m/s 80% PSV 4.6m/s 3.6m/s Cr Cr 6.3mg/dl PSV 90% PTA PSV Cr 8 1.3mg/dl PTA 12 Cr 1.3mg/dl MRA 3DCT D D dyssynchrony post systolic shortning 90% 2D
9 ,650/mm3 65%CRP 1.83mg/dl ESR 43/ CRP 3 7mg/dl CT H22 4 X effusion Myeloid/NK-cell acute leukemia effusion X CT A-aDO spontaneous echo contrast spontaneous echo contrast 1 9 spontaneous echo contrast spontaneous echo contrast spontaneous echo contrast spontaneous echo contrast CPA XP shuffle motion Tei index Tei index 95%ile Tei index congenital absence of the portal vein: CAPV
10 26 16 CAPV CAPV 1031g AS5/7 CAPV three vessel view PGE1 17 BT 22q trisomy21 37 NICU trisomy % NICU g Apgar g Apgar8/ g Apgar Score8/ congenital pouch colon congenital pouch colon pouch colon g ph AFI 35cm 29 20ml/h ml g AS 1/5 Zimmerman-Laband
11 NST cm Tei index g As 1/3 Hb3.5mg/dl cm ,500ml MTX HCCRFA B-mode RFA CT margin B-mode Sonazoid RFA B-mode HCC TOSHIBA medical Aplio mode Sonazoid RFA CT CT RFA 1 RFA S8 15mm 1 RFA Sonazoid RFA 10ml 2 4 RFA CT S4 35 US 21G Majima needle Debris CT CT
12 4 US CT 5 US % US US VAS CT 15-20ml mm mm GF-UCT240-AL5 Echotip Wilson Cook 19G EUS 14 96% 26/27 15% 4/27 4% 1/ Carotidynia Carotidynia Carotidynia 1927 Fay 1967 Roseman 1988 the International Headache Society IHS classification committee 2004 Giant cell arteritis Carotidynia Carotidynia RVS US 3D CT-lymphography SLN Real-time virtual sonography RVS US CT SLN US SLN US SLN ICG SLN SLN % ICG SLN 9 ICG SLN US SLN SLN SLN SLN mm
13 20mm cm 2.0cm CT MRI T1WI T2WI IU/m FNAC classiv CT 15 CT MRI AVM AVM CT MRI AVM CT MRI AVM
04_学術.indd
Arts and Sciences 2 Diagnostic significance of contrast-enhanced ultrasonography for hepatocellular adenoma: experiences of two cases 41080 Key words: Abdominal ultrasonography Contrast-enhanced ultrasonography
41-6_35回中部地方会Pr6N_HP掲載用.indd
₃₅ 2014 9 7 ₃₅ ₁ 1, 1, 2, 1, 1, 1, 3, 3, 3 1, 2, 3., e E E/e. CT 158,CT Volume data, CT -140-40 HU. E e, e E/e. e,e/e,. ₃₅ ₂ 1, 1, 1, 1, 2, 2, 3, 2, 2 1, 2, 3 82, T,.. S, 13 mmhg,,, 10γ S 260 mmhg,. S,.,
Microsoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
02-56fl]’_„o68fl]”îá⁄-…v…“…O…›…•
![02-56fl]’_„o68fl]”îá⁄-…v…“…O…›…•](/thumbs/48/23858159.jpg "02-56fl]’_„o68fl]”îá⁄-…v…“…O…›…•")
8:55 9:00 19:00 9:32 29:32 10:04 AVF10:04 10:28 AVM10:28 11:00 111:00 11:24 211:24 11:48 12:00 13:10 13:10 13:20 13:20 14:20 14:20 14:30 14:30 14:46 14:46 15:10 115:10 15:42 215:42 16:14 16:14 9:00 9:24
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
untitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01
2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
59 20 : 50 : : : : : 2 / :20 / 25 GTP /28 5/3 5/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3 :78 / :156/78mmHg 1
59 20 : 50 : 2005 9 : 2006 1 : 2006 4 : :2 / :20 / 25 GTP 2006 1 4/28 5/35/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3:78 / :156/78mmHg 1 0.3g 1 30-49 Hb9.5g/dL 7 /mm 3 - Cr1.6mg/dL CRP1.84 mg/dl
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
がん診療におけるFDG FDG-PET/CTの役割
PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT
天草郡市医師会第139回(臨時)代議員会
A 97 2(B A2) 4(A B3) 2 95 B 104 25(A B3) 16(B A2) 9 113 201 27 20 7 208 2 1 13 3 18 4 19 3 3 2 2 13 4 17 3 18 6 26 6 30 17 18 17 17 17 17 18 ( ) 18 ( ) 18 ( ) 18 ( ) 18 ( ) ( ) ( ) ( ) ( ) ( ) 18 ( ) (
2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml
0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
1 Blood chemistry Peripheral blood Viral marker TP 5.4 g dl WBC 4.310 3 ml Syphilis TPAb Alb 2.7 g dl RBC30210 4 ml HBsAg T. bil 2.3 mg dl Hb 11 g dl
2012; 18: 200 207 Necropsy 1 1 1 2 65 11 autoimmune hepatitisaih 14 21 1 5 13 Necropsy CHF1 A1 Kupffer cell hemosiderin Berlin blue KEY WORDS: hemochromatosis, autoimmune hepatitis, liver cirrhosis, necropsy
スライド 1
CT May 23, 2009 MDCT ~ 350 135mL ~ Clinical Experience with Highest Iodine Dose (630mgI/kg) of 135mL Syringe (Iomeprol 350mgI/mL) in Multiphasic MDCT of Liver Backgrounds A. multiphasic study for detecting
福岡大学人文論叢47-3
679 pp. 1 680 2 681 pp. 3 682 4 683 5 684 pp. 6 685 7 686 8 687 9 688 pp. b 10 689 11 690 12 691 13 692 pp. 14 693 15 694 a b 16 695 a b 17 696 a 18 697 B 19 698 A B B B A B B A A 20 699 pp. 21 700 pp.
untitled
5 10% 1 13 15cm 3 4cm 2 RS P Rb Ra S RS Ra Rb P 4 S RS CT MRI Stage 0 Stage I Stage I Stage II Ra Rb P TEM TEM ISR TEM Transanal endoscopic microsurgery 5cm 4cm 5cm TEM 1 2 3 10cm RS 6cm Ra 4cm Rb 2cm
PowerPoint Presentation
Glioma 28% astrocytoma (WHO I) 0.28 anaplastic (WHO II/III) 0.18 Glioblastoma (WHO IV) 0.32 others 0.22 Meningioma partly malignant) 26% Pituitary adenoma 17% Neurinoma 11% Craniopharyngioma etc 5% Others
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
日本呼吸器学会雑誌第44巻第7号
Table1Laboratoryfindingsonadmission Hematology Serology LungFunctionTest WBC 7,410 /μl CRP 7.7mg/dl VC 3.12L(97.2%) Neut 66.4 % KL-6 777U/ml FEV1.0 2.35L(78.25%) Eosino 3.2 % PT (INR) 0.94 %DLCO 47.6 %
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons
54 6 2018 10 pp. 1173-1193 doi: 10.11164/jjsps.54.6_1173 1173 34 The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons 30 2018 10 27 10-1 3-6-2 HP URL https://psjm2018.com/ 34 PSJM2018
次世代育成支援行動計画
15 7 10 300 9 17 21 5 21 22 5 1 2 3 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 16 39 40 11 2 3 P P 41 42 13 3 70.4 86.0 33.3 35.1 75.3 91.5 28.8 36.2 49.0 28.7 14.0 10.0
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
07.報文_及川ら-二校目.indd
8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006
マニュアル第４版表紙PDF
5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.
「東日本大震災に係る対応―保険診療・地域医療再生基金・災害復旧費補助金・医療法等について（第1報）」について
2012 3 28 2011 3 1 1 2012 3 2012 3 28 2012 3 28 2012 3 28 2012 3 28 1. 1 3 11 1 2 3 15 17 3 4 5 1 2012 3 28 5 10 6 3 18 7 5 8 3 23 9 2 2012 3 28 2011 3 23 23 10 3 2012 3 28 4 2012 3 28 5 2012 3 28 3 24
untitled
1 Session 1 9 00 10 00 10 4 1 1-001 CBCT 1-002 CT 1-003 FOV 1-004 Area detector CT 1-005 CT Modulation Transfer Function 1 2 3 4 5 6 7 8 1-006 CT Noise power spectrum 1 2 3 4 5 67 8 Session 2 10 00 10
21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
30 Fisher 2 t 結果 FIM 3 FIM ADL 考察 FIM ADL ADL ADL 結論 ADL 50 FIM ADL FIM 今後の展望 ADL 30 ADL ADL 1 FIM
29 大学院博士論文要旨 FIM? 櫻井 宏明 はじめに FIM Functional Independence Measure FIM ADL Activities of Daily Living FIM ADL 65 74 75 ADL 目的 FIM 方法 438 1 65 84 286 150 136 ADL FIM 3 FIM 30 60 90 120 FIM 44 0.7 3 Tukeykramer
WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
S24-2411 S24-2211 S22-2321 S24-2421 S24-2311 20
TOSHIBA S24-2411 S24-2211 S22-2321 S24-2421 S24-2311 20 S24-3321 S24-3341 S24-3331 S24-3211 21 S24-3361 S24-3381 S24-3371 S24-3351 S24-3221 22 S25-5511 S24-5321 S24-5411 S24-5111 23 S24-5541 S24-5521 S24-5531
日本呼吸器学会雑誌第44巻第1号
β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb
Folie 1
low-b DWI IVIM,MSDE -- -- Makoto Obara Philips Electronics Japan Bfactor IVIM: Diffusion & Perfusion MSDE: Black Blood imaging IVIM: Diffusion & Perfusion MSDE: Black Blood imaging 40 2.5 * 10-3 mm 2 /sec
051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
全国循環器撮影研究会 HP講座No
HP No.6 4 HP No.6 4 NTT 1. 1936 1953 Seldinger Seldinger 1956 Odman X Interventional Radiology IVR 1967 Margulis 1964 Dotter 2. 2.1 IVR CT MR IVR 2.2-1 - HP No.6 4 2.3 feeding artery parasitic supply increased
Contents 4 06 IP2 41 Thermo Scientific Nalgene Nalgene
Nalgene & Packaging plastic Bottles & Vials Contents 4 06 IP2 41 Thermo Scientific Nalgene 5 07 42 8 08 43 9 09 45 11 10 46 Nalgene 12 11 50 13 12 53 01 20 13 61 02 28 14 64 03 33 15 66 04 37 16 / 67 05
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
日本呼吸器学会雑誌第47巻第6号
Fig.1 A,ChestX-rayfilm demonstratingatumorshadow intherightlowerlungfield.b,chestct scan demonstratingtherightmiddlelobemass,measuring9.0 7.3cm.C,AbdominalCT scanshowingfree airintheabdominalcavityanddirtyfatsignaroundthesigmoidcolontumor.
